Glioblastoma: Advances in Molecular Insights and Therapeutic Strategies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (10 April 2024) | Viewed by 983
Special Issue Editor
Interests: glioblastoma
Special Issue Information
Dear Colleagues,
Glioblastoma (GBM) still remains as the deadliest malignant type of primary astrocytoma with an extremely poor prognosis. The standard of care for GBM typically involves surgical resection followed by radiotherapy concomitant with chemotherapy and temozolomide. New molecular insights into multiple aspects of gliomagenesis and significant advances in the treatment of GBM have been achieved in recent decades. Despite these advances, recurrence is almost always certain in GBM, which paves the way to its dismal prognosis. A wide range of factors contribute towards GBM aggressiveness, including, but not limited to, its complex microenvironment, tumor heterogeneity, glioblastoma stem cells (GBSCs), and the presence of the blood–brain barrier (BBB). Several new advances have also been made in conventional treatment strategies involving surgery, radiotherapy, and chemotherapy, as well as in newer treatment approaches like gene therapy, immunotherapy, nanotherapy, phototherapy, etc.
This Special Issue of Cancers aims to invite original research articles or review articles covering the above-mentioned topics or that provide new potential promising insights into GBM biology and treatment.
Dr. Justin V. Joseph
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
